Background Alzheimer's disease (AD) is a neurodegenerative disease caused by the
formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles. Acetylcholinesterase …

Alzheimer's disease (AD) has become one of the deadliest diseases for human beings with
special incidence in elderly population. It is a progressive neurodegenerative disease and …

Alzheimer's disease (AD) is a main cause of dementia, accounting for up to 75% of all
dementia cases. Pathophysiological processes described for AD progression involve …

As acetylcholinesterase (AChE) inhibitors are an important therapeutic strategy in
Alzheimer's disease, efforts are being made in search of new molecules with anti-AChE …

Abstract Alzheimer's disease (AD), is the most common type of dementia primarily affecting
the later years of life. Its prevalence is likely to increase in any aging population and will be a …

Alzheimer's disease, a progressive neurodegenerative disease, is characterised by
hypofunction of acetylcholine (ACh) neurotransmitter in the distinct region of brain …

The inhibition of acetylcholinesterase (AChE) has been one of the most used strategies for
the treatment of Alzheimer's disease (AD). The AChE inhibitors (AChE-I) produce not only …

Inhibition of acetylcholinesterase (AChE), the key enzyme in the breakdown of acetylcholine,
is considered as a promising strategy for the treatment of neurological disorders such as …

Alzheimer's disease rises with predictions of 115 million being affected by 2050 due to aging
of the population, continuing lack of progress in identifying, effective treatment modalities …

Acetylcholinesterase (AChE), the predominant cholinesterase in the brain, hydrolyzes ACh
to choline and acetate, thereby terminating the effect of this neurotransmitter at cholinergic …